小剂量来氟米特配合甲氨蝶呤治疗老年类风湿关节炎患者的效果

doi:10.3760/cma.j.issn.1007-1245.2024.09.020

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (9): 1498-1502.DOI: 10.3760/cma.j.issn.1007-1245.2024.09.020

小剂量来氟米特配合甲氨蝶呤治疗老年类风湿关节炎患者的效果

盖楠楠¹ 郭华^1,2 张洁¹ 鲍蕴琦¹

¹西安市第五医院风湿免疫科，西安　710082；²西安市中心医院骨科，西安　710003

收稿日期:2023-12-11 出版日期:2024-05-01 发布日期:2024-05-31
通讯作者: 鲍蕴琦，Email：byq_fudan@163.com
基金资助:
陕西省重点研发计划（2019SF-177）；西安市科技计划（22YXYJ0004）

Low-dose leflunomide combined with methotrexate for elderly patients with rheumatoid arthritis

Gai Nannan¹, Guo Hua^1,2, Zhang Jie¹, Bao Yunqi¹

¹Department of Rheumatology and Immunology, Xi'an Fifth Hospital, Xi'an 710082, China; ²Department of Orthopedics, Xi'an Central Hospital, Xi'an 710003, China

Received:2023-12-11 Online:2024-05-01 Published:2024-05-31
Contact: Bao Yunqi, Email: byq_fudan@163.com
Supported by:
Plan of Key Research and Development in Shaanxi (2019SF-177); Plan of Science and Technology in Xi'an (22YXYJ0004)

摘要/Abstract

摘要：

目的　探讨小剂量来氟米特配合甲氨蝶呤治疗老年首发类风湿关节炎（rheumatoid arthritis，RA）患者的效果。方法　选取2020年2月至2023年2月西安市第五医院收治的120例老年首发RA患者进行随机对照试验。采用随机数字表法将其分为配合组及参考组，各60例。配合组男37例，女23例，年龄（70.22±5.29）岁，体质量指数（body mass index，BMI）（22.87±1.55）kg/m²，病程（4.76±0.85）年。参考组男38例，女22例，年龄（70.31±5.34）岁，BMI（22.94±1.58）kg/m²，病程（4.82±0.87）年。参考组采用甲氨蝶呤治疗，配合组则于参考组的基础上采用小剂量来氟米特治疗。两组均治疗90 d。对比两组临床疗效，临床症状改善情况，治疗前后骨代谢指标水平和血清壳多糖酶3样蛋白1（chitinase 3-like protein1，CHI3L1）、可溶性基质裂解素2（soluble suppression of tumorigenicity 2，sST2）、白细胞介素-32（interleukin-32，IL-32）水平，不良反应。采用χ²检验和t检验。结果　配合组总有效率高于参考组［96.67%（58/60）比83.33%（50/60）］（χ²=5.926，P=0.015）。配合组关节压痛数目、关节肿胀数目分别为（5.23±1.05）个、（4.18±0.66）个，均少于参考组的（7.45±1.36）个、（6.39±0.82）个，晨僵时长为（34.58±4.68）min，短于参考组的（50.40±8.21）min，双手握力为（14.03±2.55）kPa，高于参考组的（11.28±2.09）kPa（t=10.008、16.263、12.967、6.461，均P<0.001）。治疗后，配合组骨钙素（bone gla protein，BGP）、骨保护素（osteoprotectin，OPG）及总Ⅰ型胶原氨基端延长肽（total type I collagen amino terminal extension peptide，T-PⅠNP）水平分别为（27.48±5.02）ng/L、（5.02±0.74）ng/L、（43.17±8.59）μg/L，均高于参考组的（24.16±4.19）ng/L、（4.45±0.66）ng/L、（36.92±7.33）μg/L（t=3.933、4.453、4.287，均P<0.001）。治疗后，配合组血清CHI3L1、sST2、IL-32水平分别为（50.82±6.12）μg/L、（28.45±4.11）μg/L、（14.32±2.01）ng/L，均低于参考组的（78.45±8.39）μg/L、（33.05±5.24）μg/L、（16.85±2.77）ng/L（t=20.609、5.350、5.726，均P<0.001）。两组不良反应发生率对比，差异无统计学意义（P>0.05）。结论　小剂量来氟米特配合甲氨蝶呤应用于老年首发RA患者中的效果较佳，可改善患者骨代谢指标及血清CHI3L1、sST2、IL-32水平。

关键词:

类风湿关节炎, 来氟米特, 甲氨蝶呤, 壳多糖酶3样蛋白1, 可溶性基质裂解素2, 白细胞介素-32

Abstract:

Objective　To investigate the effect of low-dose leflumide combined with methotrexate for elderly patients with first-episode rheumatoid arthritis (RA). Methods　One hundred and twenty elderly patients with first-episode RA admitted to Xi'an Fifth Hospital from February 2020 to February 2023 were selected for the randomized controlled trial. They were divided into a combination group and a reference group by the random number table method, with 60 cases in each group. There were 37 males and 23 females in the combination group; they were (70.22±5.29) years old; their body mass index (BMI) was (22.87±1.55) kg/m²; their disease course was (4.76±0.85) years. There were 38 males and 22 females in the reference group; they were (70.31±5.34) years old; their BMI was (22.94±1.58); their disease course was (4.82±0.87) years. The reference group were treated with methotrexate, and the combination group with low-dose leflunomide and methotrexate, for 90 d. The clinical efficacies, improvement of clinical symptoms, levels of bone metabolism indicators and serum levels of chitinase 3-like protein1 (CHI3L1), soluble suppression of tumorigenicity 2 (sST2), and interleukin-32 (IL-32) before and after the treatment, and adverse reactions were compared between the two groups. χ² and t tests were applied. Results　The total effective rate of the combination group was higher than that of the reference group [96.67% (58/60) vs. 83.33% (50/60); χ²=5.926, P=0.015]. The joint number with tenderness, joint number with swelling, duration of morning stiffness, and grip strength of both hands in the combination group were better than those in the control group [(5.23±1.05) vs. (7.45±1.36), (4.18±0.66) vs. (6.39±0.82), (34.58±4.68) min vs. (50.40±8.21) min, and (14.03±2.55) kPa vs. (11.28±2.09) kPa; t=10.008, 16.263, 12.967, and 6.461; P<0.001]. After the treatment, the levels of bone gla protein (BGP), osteoprotectin (OPG), and total type Ⅰ collagen amino terminal extension peptide (T-PⅠNP) in the combination group were higher than those in the reference group [(27.48±5.02) ng/L vs. (24.16±4.19) ng/L, (5.02±0.74) ng/L vs. (4.45±0.66) ng/L, and (43.17±8.59) μg/L vs. (36.92±7.33) μg/L; t=3.933, 4.453, and 4.287; all P<0.001]. After the treatment, the serum levels of CHI3L1, sST2, and IL-32 in the combination group were lower than those in the reference group [(50.82±6.12) μg/L vs. (78.45±8.39) μg/L, (28.45±4.11) μg/L vs. (33.05±5.24) μg/L, and (14.32±2.01) ng/L vs. (16.85±2.77) ng/L; t=20.609, 5.350, 5.726; all P<0.001]. There was no statistical difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion　Low-dose leflunomide combined with methotrexate for elderly patients with first-episode RA is effective, and can significantly improve their bone metabolism indicators and serum levels of CHI3L1, sST2, and IL-32.

Key words:

Rheumatoid arthritis, Leflunomide, Methotrexate, Chitinase 3-like protein 1, Soluble matrix lysin 2, Interleukin-32

盖楠楠郭华张洁鲍蕴琦.

小剂量来氟米特配合甲氨蝶呤治疗老年类风湿关节炎患者的效果 [J]. 国际医药卫生导报, 2024, 30(9): 1498-1502.

Gai Nannan, Guo Hua, Zhang Jie, Bao Yunqi.

Low-dose leflunomide combined with methotrexate for elderly patients with rheumatoid arthritis [J]. International Medicine and Health Guidance News, 2024, 30(9): 1498-1502.

参考文献

参考文献
[1] Castro-Gutierrez A, Young K, Bermas BL. Pregnancy and management in women with rheumatoid arthritis, systemic lupus erythematosus, and obstetric antiphospholipid syndrome [J]. Rheum Dis Clin North Am, 2022, 48(2):523-535. DOI: 10.1016/j.rdc.2022.02.009.
[2] Tizaoui K, Yang JW, Lee KH, et al. The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review [J]. Int J Biol Sci, 2022, 18(9):3731-3746. doi: 10.7150/ijbs.67587.
[3] 张伟,郭慧娟,刘运洪,等. 类风湿关节炎患者血清中sST2水平与疾病活动度的相关性[J]. 西部医学,2021,33(7):1069-1072. DOI:10.3969/j.issn.1672-3511.2021.07.028.
[4] 陈如平,吴华杰. 四妙勇安汤合白虎汤加味辨治类风湿关节炎湿热痹阻证疗效及对血清sTREM-1、IL-32、GPI水平的影响[J]. 新中医,2021,53(11):36-40. DOI: 10.13457/j.cnki.jncm.2021.11.010.
[5] 中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018, 57(4): 242-251. DOI:10.3760/cma.j.issn.0578-1426.2018.04.004.
[6] 李树岗,宋远瑛. 皂芥二陈汤联合来氟米特治疗痰瘀痹阻证类风湿关节炎疗效及对血清IL-33、BMP-2、GM-CSF的影响[J]. 现代中西医结合杂志,2021,30(4):403-407. DOI:10.3969/j.issn.1008-8849.2021.04.013.
[7] Narváez J, Aburto M, Seoane-Mato D, et al. Screening criteria for interstitial lung disease associated to rheumatoid arthritis: expert proposal based on Delphi methodology [J]. Reumatol Clin (Engl Ed), 2023, 19(2):74-81. DOI: 10.1016/j.reumae.2021.12.003.
[8] 陈爱党,康宁,郭建洲. 白芍总苷胶囊联合来氟米特治疗对类风湿关节炎患者炎性因子、心肌酶谱及不良反应的影响[J]. 实用医院临床杂志,2022,19(5):131-134. DOI:10.3969/j.issn.1672-6170.2022.05.036.
[9] 韩玉艳,黄露露,杨梦妮,等. 艾拉莫德或甲氨蝶呤联合来氟米特治疗活动性老年类风湿关节炎104例[J]. 中国新药杂志,2023,32(17):1749-1755. DOI:10.3969/j.issn.1003- 3734.2023.17.009.
[10] 李艳琴,孙强. 来氟米特联合甲氨蝶呤治疗类风湿关节炎患者的疗效及对血清生长因子的影响[J]. 实用临床医药杂志,2020,24(21):108-111. DOI:10.7619/jcmp.202021031.
[11] 马沙. 甲氨蝶呤与来氟米特联用对类风湿关节炎患者促炎症细胞因子与VAS疼痛评分水平及其肿胀疼痛关节数的影响[J]. 抗感染药学,2020,17(9):1388-1389,1398. DOI:10.13493/j.issn.1672.7878.2020.09-045.
[12] 刘童,李兴锐,陆继娣,等. 来氟米特联合小剂量甲泼尼龙对类风湿关节炎患者Th17/Treg细胞比值影响[J]. 临床军医杂志,2021,49(11):1239-1241. DOI:10.16680/j.1671- 3826.2021.11.19.
[13] 沈海涛,焦荣红,谢钰帆. 血清CHI3L1、Clusterin对类风湿关节炎活动度及治疗反应性的预测价值分析[J]. 国际检验医学杂志,2023,44(7):857-861. DOI:10.3969/j.issn.1673- 4130.2023.07.017.
[14] 毛显轲. 血清sST2、MMP-3、RF在类风湿关节炎患者病情评估及疗效监测中的价值[J]. 中外医学研究,2022,20(33):17-21. DOI: 10.14033/j.cnki.cfmr.2022.33.005.
[15] 李婧,叶志勤. 宣痹汤合三妙散联合西药口服对类风湿关节炎湿热痹阻证患者疗效及血清sTREM-1、IL-32、GPI水平的影响[J]. 西部中医药,2022,35(7):86-89. DOI: 10.12174/j.issn.2096-9600.2022.07.23.

小剂量来氟米特配合甲氨蝶呤治疗老年类风湿关节炎患者的效果

Low-dose leflunomide combined with methotrexate for elderly patients with rheumatoid arthritis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

[1]	王鹏飞王延妮姜萍. 张鸣鹤和范永升教授辨治类风湿关节炎的用药规律 [J]. 国际医药卫生导报, 2024, 30(7): 1161-1166.
[2]	卫莎林文涛赵婷婷牛艳妮张妮娜. 托法替布联合艾拉莫德治疗类风湿关节炎的效果及对细胞免疫功能的影响 [J]. 国际医药卫生导报, 2023, 29(20): 2883-2886.
[3]	李慧颖姜国平　吕英春. 托法替布联合甲氨蝶呤治疗类风湿关节炎的疗效研究 [J]. 国际医药卫生导报, 2023, 29(10): 1413-1416.
[4]	时娟娟, 张久严, 杨慧, 崔秀娟, 张丹. 消癥复通汤联合甲氨蝶呤治疗异位妊娠的临床疗效研究[J]. 国际医药卫生导报, 2022, 28(12): 1636-1640.